| Biomarker ID | 881 |
| PMID | 22355332 |
| Year | 2012 |
| Biomarker | cDNA FLJ54228 + Alpha-1-antichymotrypsin+ Complement component C9b+ cDNA FLJ58564 + Complement C5+Ceruloplasmin+cDNA FLJ55673 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated [cDNA FLJ54228 (2.2 fold)+ Alpha-1-antichymotrypsin (1.8 fold)+ Complement component C9b (1.4 fold)+ cDNA FLJ58564 (1.3 fold) + Complement C5 (1.3 fold) +Ceruloplasmin (1.2 fold) +cDNA FLJ55673 (1.1 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Progressing Vs Metastatic Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | Samples were collected from 4 groups with 5 samples each:benign prostatic hyperplasia (BPH); ii) localised cancer with no evidence of progression, (non-progressing) (iii) localised cancer with evidence of biochemical progression, (progressin), and (iv) bone metastasis at presentation (metastatic). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p ≤0.01 |
| Method Used | 4-plex iTRAQ |
| Clinical | No |
| Remarks | represents biomarkers assessed individualy, + represents biomarkers assessed as a pair or panel |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SERPINA3, C5, CP |